Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study von Lee, Chung-Han, Shah, Amishi Yogesh, Rasco, Drew, Rao, Arpit, Taylor, Matthew H, Di Simone, Christopher, Hsieh, James J, Pinto, Alvaro, Shaffer, David R, Girones Sarrio, Regina, Cohn, Allen Lee, Vogelzang, Nicholas J, Bilen, Mehmet Asim, Gunnestad Ribe, Sara, Goksel, Musaberk, Tennøe, Øyvind Krohn, Richards, Donald, Sweis, Randy F, Courtright, Jay, Heinrich, Daniel, Jain, Sharad, Wu, Jane, Schmidt, Emmett V, Perini, Rodolfo F, Kubiak, Peter, Okpara, Chinyere E, Smith, Alan D, Motzer, Robert J

Volltext

Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146 von Lee, Chung-Han, Yogesh Shah, Amishi, Rao, Arpit, Taylor, Matthew H., Di Simone, Christopher, Hsieh, James J., Pinto, Alvaro, Gironés Sarrió, Regina, Lee Cohn, Allen, Asim Bilen, Mehmet, Gunnestad Ribe, Sara, Krohn Tennøe, Øyvind, Richards, Donald, Sweis, Randy F., Courtright, Jay, Heinrich, Daniel, Perini, Rodolfo, Kubiak, Peter, Bock, Daena, Okpara, Chinyere E., Motzer, Robert J.

Volltext

Lenvatinib in Combination With Pembrolizumab in Patients with Treatment-Naïve and Treatment-Experienced Metastatic Renal Cell Carcinoma: Results From a Phase 1b/2 Study von Lee, Chung-Han, Shah, Amishi Yogesh, Rasco, Drew, Rao, Arpit, Taylor, Matthew H., Di Simone, Christopher, Hsieh, James J., Pinto, Alvaro, Shaffer, David R., Sarrio, Regina Girones, Cohn, Allen Lee, Vogelzang, Nicholas J., Bilen, Mehmet Asim, Ribe, Sara Gunnestad, Goksel, Musaberk, Tennøe, Øyvind Krohn, Richards, Donald, Sweis, Randy F., Courtright, Jay, Heinrich, Daniel, Jain, Sharad, Wu, Jane, Schmidt, Emmett V., Perini, Rodolfo F., Kubiak, Peter, Okpara, Chinyere E., Smith, Alan D., Motzer, Robert J.

Volltext

Final database lock results of the phase 2 cohort of lenvatinib + pembrolizumab for progressive disease after a PD-1/PD-L1-containing therapy in metastatic clear cell renal cell ca... von Lee, Chung-Han, Yogesh Shah, Amishi, Rao, Arpit, Taylor, Matthew H, Pinto, Alvaro, Girones Sarrio, Regina, Lee Cohn, Allen, Asim Bilen, Mehmet, Gunnestad Ribe, Sara, Goksel, Musaberk, Tennøe, Øyvind Krohn, Richards, Donald, Sweis, Randy F, Heinrich, Daniel, Perini, Rodolfo, Kubiak, Peter, Huang, Jie, Motzer, Robert J

Volltext

Lenvatinib (LEN) + pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial von Lee, Chung-Han, Shah, Amishi Yogesh, Hsieh, James J, Rao, Arpit, Pinto, Alvaro, Bilen, Mehmet Asim, Cohn, Allen Lee, DiSimone, Christopher, Shaffer, David R., Gironés Sarrió, Regina, Gunnestad Ribe, Sara, Wu, Jane, Schmidt, Emmett V., Kubiak, Peter, Okpara, Chinyere, Smith, Alan D., Motzer, Robert J.

Volltext

Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcin... von Lee, Chung-Han, Shah, Amishi Yogesh, Hsieh, James J, Rao, Arpit, Pinto, Alvaro, Bilen, Mehmet Asim, Cohn, Allen Lee, Di Simone, Christopher, Shaffer, David R., Girones Sarrio, Regina, Gunnestad Ribe, Sara, Wu, Jane, Schmidt, Emmett V., Perini, Rodolfo F., Kubiak, Peter, Smith, Alan D., Motzer, Robert J.

Volltext